Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Fleming Alison B

2. Date of Event Requiring Statement (MM/DD/YYYY) 1/4/2017

3. Issuer Name and Ticker or Trading Symbol

COLLEGIUM PHARMACEUTICAL, INC [COLL]

(Last) (First) (Middle)

780 DEDHAM STREET, SUITE 800

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
Chief Scientific Officer /

(Street)

CANTON, MA 02021

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock ⁽¹⁾	7211	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to purchase)	⁽²⁾	11/1/2017	Common Stock	1811	$3.38	D
Stock Option (right to purchase)	⁽³⁾	4/23/2019	Common Stock	1811	$.90	D
Stock Option (right to purchase)	⁽⁴⁾	2/26/2020	Common Stock	1811	$.90	D
Stock Option (right to purchase)	⁽⁵⁾	2/8/2021	Common Stock	1449	$3.31	D
Stock Option (right to purchase)	⁽⁶⁾	1/24/2023	Common Stock	12681	$.48	D
Stock Option (right to purchase)	⁽⁷⁾	3/5/2024	Common Stock	6175	$.28	D
Stock Option (right to purchase)	⁽⁸⁾	3/5/2024	Common Stock	5728	$.28	D
Stock Option (right to purchase)	⁽⁹⁾	3/19/2025	Common Stock	60378	$5.73	D
Stock Option (right to purchase)	⁽¹⁰⁾	5/18/2025	Common Stock	10000	$15.60	D
Stock Option (right to purchase)	⁽¹¹⁾	1/20/2026	Common Stock	29475	$16.15	D

Explanation of Responses:
( 1)	Includes 4,913 restricted stock units granted to Ms. Fleming on January 20, 2016. Pursuant to the grant, each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest over a four-year period commencing on January 20, 2016. Twenty-five percent (25%) of the restricted stock units vest on January 20, 2017, and the balance of the restricted stock units vest in equal installments every six months (in each case, rounded up to the nearest whole share) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer. The restricted stock units will be settled on each applicable vest date in shares of the issuer's common stock.
( 2)	All 1,811 option shares are exercisable.
( 3)	All 1,811 option shares are exercisable.
( 4)	All 1,811 option shares are exercisable.
( 5)	All 1,449 option shares are exercisable.
( 6)	12,417 option shares are exercisable. The option vests and becomes exercisable in equal installments (rounded up to the nearest whole share) at the end of each month over a four-year period commencing on January 24, 2013, subject to the employee's continued service with the issuer.
( 7)	1,300 option shares are exercisable. The option, representing a right to purchase a total of 15,623 shares, vests and becomes exercisable in equal installments (rounded up to the nearest whole share) on a monthly basis over a four-year period commencing on March 5, 2014, subject to the employee's continued service with the issuer.
( 8)	1,208 option shares are exercisable. The option, representing a right to purchase a total of 14,492 shares, vests and becomes exercisable over a four-year period commencing on March 5, 2014. Twenty-five percent (25%) of the option vested and became exercisable on March 5, 2015 and then in equal monthly installments (rounded up to the nearest whole share) at the end of each monthly period over the remaining three years of the four-year period, subject to the employee's continued service with the issuer.
( 9)	26,421 option shares are exercisable. The option vests and becomes exercisable in equal installments (rounded up to the nearest whole share) on a monthly basis over a four-year period commencing on March 19, 2015, subject to the employee's continued service with the issuer.
( 10)	3,958 option shares are exercisable. The option vests and becomes exercisable over a four-year period commencing on May 18, 2015. Twenty-five percent (25%) of the option vested and became exercisable on May 18, 2016, and the balance vests in equal monthly installments (rounded up to the nearest whole share) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer.
( 11)	The option vests and becomes exercisable over a four-year period commencing on January 20, 2016. Twenty-five percent (25%) of the option vests and becomes exercisable on January 20, 2017, and the balance vests in equal monthly installments (rounded up to the nearest whole share) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Fleming Alison B 780 DEDHAM STREET, SUITE 800 CANTON, MA 02021			Chief Scientific Officer

Signatures
/s/ Paul Brannelly as Attorney-In-Fact For Alison B. Fleming		1/17/2017
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.